文章摘要
高 华,石海萍,张权武,肖攀云,张喜平.康复新液辅助纤维支气管镜灌注联合化疗对耐多药肺结核患者肺功能、炎症因子和T淋巴细胞亚群的影响[J].,2020,(21):4147-4151
康复新液辅助纤维支气管镜灌注联合化疗对耐多药肺结核患者肺功能、炎症因子和T淋巴细胞亚群的影响
Effect of Kangfuxinye Oral Supplementary Fiberoptic Bronchoscopic Infusion Chemotherapy on Multidrug-resistant Pulmonary Tuberculosis
投稿时间:2020-04-07  修订日期:2020-04-28
DOI:10.13241/j.cnki.pmb.2020.21.033
中文关键词: 康复新液  纤维支气管镜灌注  化疗  耐多药肺结核  肺功能  炎症因子  T淋巴细胞亚群
英文关键词: Kangfuxinye  Fiberoptic bronchoscopic infusion  Chemotherapy  Multidrug-resistant pulmonary tuberculosis  Pulmonary function  Inflammatory factors  T lymphocyte subsets
基金项目:陕西省卫生健康委员会科研基金项目(2018D1446)
作者单位E-mail
高 华 陕西省结核病防治院结核内科 陕西 西安 710100 GH15091836444@163.com 
石海萍 陕西省结核病防治院结核内科 陕西 西安 710100  
张权武 陕西省结核病防治院结核内科 陕西 西安 710100  
肖攀云 陕西省结核病防治院结核内科 陕西 西安 710100  
张喜平 陕西省结核病防治院结核内科 陕西 西安 710100  
摘要点击次数: 517
全文下载次数: 339
中文摘要:
      摘要 目的:探讨康复新液辅助纤维支气管镜灌注联合化疗对耐多药肺结核患者肺功能、炎症因子和T淋巴细胞亚群的影响。方法:选取2015年1月到2017年2月期间我院收治的耐多药肺结核患者68例,根据治疗方案将患者分为对照组(n=34,纤维支气管镜灌注联合化疗)和研究组(n=34,康复新液辅助纤维支气管镜灌注联合化疗),比较两组患者临床疗效以及肺功能、炎症因子和T淋巴细胞亚群变化,记录两组治疗期间不良反应发生情况。结果:研究组治疗12个月后、治疗20个月后病灶吸收率、痰菌转阴率、空洞闭合率均高于对照组(P<0.05)。两组患者治疗6个月后第1s用力呼气容积占预计值百分比(FEV1%)、用力肺活量占预计值百分比(FVC%)、每分钟最大通气量占预计值百分比(MVV%)、γ-干扰素(IFN-γ)、CD4+、CD4+/CD8+均较治疗前升高,且研究组高于对照组(P<0.05)。两组患者治疗6个月后白介素-6(IL-6)、C反应蛋白(CRP)、CD8+均较治疗前降低,且研究组低于对照组(P<0.05)。两组患者总不良反应发生率比较无明显差异(P>0.05)。结论:康复新液辅助纤维支气管镜灌注联合化疗治疗耐多药肺结核患者,疗效理想,能够有效改善患者肺功能和免疫功能,缓解炎症反应,安全性较好,具有一定的临床应用价值。
英文摘要:
      ABSTRACT Objective: To investigate the effects of Kangfuxinye oral supplementary fiberoptic bronchoscopic infusion chemotherapy on pulmonary function, inflammatory factors and T lymphocyte subsets in patients with multidrug-resistant pulmonary tuberculosis. Methods: 68 patients with multidrug-resistant pulmonary tuberculosis who were admitted to our hospital from January 2015 to February 2017 were selected, and they were divided into control group (n=34, fiberoptic bronchoscopic infusion combined with chemotherapy) and study group (n=34, Kangfuxinye supplementary fiberoptic bronchoscopic infusion combined with chemotherapy) according to the treatment plan. The clinical efficacy, pulmonary function, inflammatory factors and T lymphocyte subsets levels of the two groups were compared. The occurrence of adverse reactions during treatment was recorded. Results: The focus absorption rate, sputum negative conversion rate and cavity closure rate of the study group after 12 months of treatment and after 20 months of treatment were higher than those of the control group (P<0.05). After 6 months of treatment, the forced expiratory volume in one second to forced vital capacity (FEV1), forced vital capacity (FVC), maximum ventilatory volume (MVV), interferon-γ (IFN-γ), CD4+, CD4+/CD8+ in both groups were higher than those before treatment, and those in the study group were higher than those in the control group (P<0.05). After 6 months of treatment, the levels of interleukin-6 (IL-6), C-reactive protein (CRP) and CD8+ in both groups were lower than those before treatment, and those in the study group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of total adverse reactions between the two groups (P>0.05). Conclusion: Kangfuxinye oral supplementary fiberoptic bronchoscopic infusion chemotherapy for multidrug-resistant pulmonary tuberculosis patients has satisfactory curative effect, it can effectively improve the pulmonary function, inflammatory reaction and immune function of patients, the safety is good, and it has a certain clinical application value.
查看全文   查看/发表评论  下载PDF阅读器
关闭